Read our SOPHiA DDM™️ Dx ROS performance evaluation study and make confident data-driven decisions that improve patient care.
Studies show that as few as 10% of people living with familial hypercholesterolemia (FH) could be aware of their diagnosis. Could genetic testing expedite early diagnosis and timely treatment?
Last week we attended the European Society for Medical Oncology (ESMO) Congress 2022, gathering the world's leading oncologists. Read our summary of three presentations illustrating cancer therapy development.
Check out our step-by-step guide to using SOPHiA DDM™️ complemented by Alamut™️ Visual Plus to streamline the interpretation of clinical exome data for neurological disorders.
Cancer management outcomes can strongly benefit from robust and accurate detection of gene fusions. SOPHiA GENETICS developed the SOPHiA DDM Dx RNAtarget Oncology Solution to make this possible.
We list 7 reasons to consider SOPHiA DDM Dx RNAtarget Oncology Solution for your assays.
Last week we attended the 2022 American Society of Clinical Oncology (ASCO) meeting, gathering the world's leading researchers in oncology. Read our summary of four groundbreaking presentations on breast cancer research.
Read our summary of new research studies presented at the European Society of Human Genetics (ESHG) Annual Conference 2022 about how next-generation sequencing is advancing pediatric healthcare.
Learn about the SOPHiA DDM Platform’s CNV detection algorithm from our Senior Algorithm Researcher, Bita Khalili.
Q&A with the Clinical Application Product Manager, Mikhail Pertziger, PhD
Next generation sequencing has greatly enhanced our power for identifying mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
Read our summary of top-rated research in the field of exome sequencing at the American College
of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2022.